Clinical Programme

Prostate Cancer

Prostate cancer is the most common form of malignancy in men and is the second leading cause of male cancer-related deaths.

Initial treatments for advancing prostate cancer focus on reducing the levels of circulating male hormones (androgens) in the body which the tumour requires for growth. Over time however, the cancer cells are able to circumvent such treatments and can develop into the castration resistant form of the disease (CRPC). This is lethal with overall survival typically less than 14 months.

PLACEHOLDER - Prostate Cancer Graphic 1

The development of CRPC is characterised by presence of functional but altered androgen receptors, which mediate the effects of male hormones. Current therapies are ineffective in reducing the activity of these altered receptors.   CCS1477 works in a different way and lowers the levels and the function of androgen receptors (AR) in prostate cancer cells, and importantly, of AR-splice variants that arise as disease progresses.  It is these variants that are thought to drive resistance to current therapeutic agents, such as Xtandi, Zytiga and Erleada. CCS1477 also effects other key oncogenes including MYC.

In an in vivo cancer xenograft model that is driven by AR-splice variants (22Rv1), CCS1477 can cause complete tumour stasis at a well tolerated dose. Anti-tumour effects are dose dependent.

Intriguingly, tumour stasis is maintained for a significant period after dosing cessation (and when drug has completely cleared from the system). This suggests some kind of reprogramming of tumours with CCS1477. It also means that there is significant scope for different dosing schedules of CCS1477, as the first-in-class drug is used in patients.

Prostate Cancer Graphic 2


Prostate Cancer Graphic 3

As well as direct effects on AR and AR-SV protein levels, CCS1477 affects downstream biomarkers of AR-inhibition and prostate cancer. In pre-clinical efficacy models, plasma PSA is profoundly reduced by dosing with CellCentric’s drug, corresponding with tumour growth inhibition. Other downstream genes are also affected including TMPRSS2 and KLK3 in tumours.

As the use of second-generation anti-hormonal drugs continues to increase, the numbers of patients that become resistant to them also continues to grow. This is now a recognised and significant population of high unmet need. CCS1477 is ideally positioned for these patients, either as a monotherapy or in combination with existing agents.